FolioStart free

Medicine · Literature

Research papers on GLP-1 drugs and weight loss

Recent and highly-cited academic work on glp-1 drugs and weight loss, gathered from Semantic Scholar, CrossRef and OpenAlex.

Search all 200M+ papers on this topic, free →Or track new glp-1 drugs and weight loss papers automatically as they publish

  2. Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis

    Peter Squire, James Naude, Ali Zentner, et al. · 2025 · BMJ Open · 43 citations

    Objectives The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies significantly. We investigated the anthropometric, demographic and clinical characteristics associated with total body weight loss (TBWL) from subcutaneous GLP-1 analogue therapy in patients with obesity in a real-world setting. Design Retrospective cohort analysis. Setting An urban, multidisciplinary obesity community clinic in Vancouver, Canada, from November 2018 to April 2021. Participants 483 adults with a body mass index (BMI) of ≧30 kg/m2 who had filled a new prescription for subcutaneous semaglutide or liraglutide, with at least 6-month follow-up, were included (mean follow-up: 17.3 months). I

    Save this paper

  3. Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study

    Hans Johnson, David Huang, Vivian N. Liu, et al. · 2024 · Journal of Medical Internet Research · 26 citations

    Background Obesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), have led to significant weight loss among users. Digital health platforms offering behavioral support may enhance the effectiveness of these medications. Objective This retrospective service evaluation investigated the impact of engagement with an app-based digital weight loss program on weight loss outcomes among individuals using GLP-1 receptor agonists (semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (tirzepatide) in t

    Save this paper

  4. Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs

    Ravi Teja Kolli, Sridevi Aoutla, Nirmal Jyothi, et al. · 2025 · Cureus · 19 citations

    Anti-obesity pharmacotherapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and orlistat, are effective for weight loss; however, weight regain following treatment discontinuation remains a major concern. This meta-analysis aimed to quantify the magnitude of weight regain after reaching peak weight loss, and to compare rebound effects across four commonly used agents: semaglutide, liraglutide, exenatide, and orlistat. A systematic search was conducted in PubMed (n = 498), Cochrane Library (n = 41), Scopus (n = 258), ScienceDirect (n = 248), and Web of Science (n = 158) from January 2010 to October 2024. After removing 153 duplicates, 950 records were screened. Following full-te

    Save this paper

  5. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration

    Alhussain Khawaji, Abdulaziz A. Jaly, Hanan A. Bakri, et al. · 2025 · Journal of Obesity · 14 citations

    Introduction: Tirzepatide, a dual glucose‐dependent insulinotropic peptide (GIP) and glucagon‐like Peptide 1 (GLP‐1) analogue, is a novel medication with comparable pharmacological characteristics and has demonstrated promising weight reduction outcomes in its antidiabetic trials following the approval of liraglutide and semaglutide for long‐term weight control. Nonetheless, this efficacy has not been fully explored, so this meta‐analysis was aimed to measure the weight loss efficacy and safety of tirzepatide in adults with overweight or obesity.

    Save this paper

  6. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children

    Hussein Zaitoon, A. Wauters, L. Rodríguez, et al. · 2025 · Children · 12 citations

    Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a transformative therapy for obesity and type 2 diabetes (T2D) in pediatric populations. This review synthesizes current evidence on efficacy, safety, and knowledge gaps in children and adolescents. Methods: A structured review of randomized controlled trials, extension studies, and mechanistic investigations evaluating GLP-1RAs in pediatric obesity and T2D was conducted. Outcomes of interest included body weight, BMI, body composition, glycemic control, and adverse events. Results: In adolescents, liraglutide and semaglutide consistently produce clinically meaningful reductions in BMI, body weight, a

    Save this paper

  7. Weight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.

    A. Scheen · 2025 · Diabetes & metabolism · 11 citations

    BACKGROUND Obesity is an increasing public health problem because of its high prevalence and associated morbidity and mortality. Two weight-loss strategies are currently used, either bariatric surgery or pharmacological therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs). Preclinical studies in rodents suggested an increased risk of additive disorders after bariatric surgery contrasting with a reduced risk with GLP-1RAs. METHODS An extensive literature search to detect clinical studies that investigated the prevalence of addictive disorders (food addiction, alcohol abuse, smoking, cannabis, cocaine, opioid use) following bariatric surgery or GLP-1RA therapy in obese patients.

    Save this paper

  9. Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review

    Zeyu Xie, Zhuoru Liang, Yilin Xie, et al. · 2025 · Diabetes, Metabolic Syndrome and Obesity · 10 citations

    Purpose Tirzepatide, a dual GLP-1/GIP agonist, shows promise for weight loss, but its safety compared to GLP-1 receptor agonists requires (liraglutide, semaglutide) clarification for clinical decision-making. This systematic review evaluates their safety profiles in patients with obesity or overweight. Methods We conducted a PRISMA-compliant systematic review (PROSPERO: CRD42024576314) of RCTs from PubMed, Embase, and Cochrane (inception to August 20, 2024). Adults with BMI ≥27 kg/m² (≥25 kg/m² for Asians) receiving GLP-1/GIP dual agonists (tirzepatide 10 or 15 mg) and GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3.0 mg) were included. Network meta-analysis (NMA) was conducted

    Save this paper

  10. 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide

    Mun-Teng Wong, Pei-Hsuan Lin, Wei-Chen Lin, et al. · 2025 · Journal of Medicinal Chemistry · 10 citations

    Conjugating two fatty acids (2FAs) to peptide drugs can improve pharmacokinetics and therapeutic effects. However, optimizing FA spacing, chain combination, and attachment site to simultaneously enhance albumin binding and drug efficacy remains challenging. We introduce a multiarm linker technology enabling precise control of 2FA spacing, composition, and attachment. By applying this technology to a modified glucagon-like peptide-1 (GLP-1) and screening various 2FA-GLP-1 conjugates differing in linkage, linker, and FA properties for improved albumin affinity, pharmacokinetics, and pharmacodynamics, TE-8105 emerged as a promising candidate. TE-8105 outperformed semaglutide, showing improved l

    Save this paper

  11. Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery

    Hussein Abdallah, W. Klink, J. Derienne, et al. · 2025 · Obesity Surgery · 10 citations

    Bariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain. Glucagon-like peptide-1 receptor agonists (arGLP-1) have emerged as a promising adjunctive therapy for managing these suboptimal outcomes. This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS. A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post

    Save this paper

  12. Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists

    Marwah Shah, Ahmad Mohammad, Rabia Bashir Ahmed Samejo, et al. · 2025 · Cureus · 8 citations

    This systematic review evaluates the long-term efficacy and safety of GLP-1 receptor agonists in the management of obesity, focusing on data from high-quality randomized controlled trials published between 2018 and 2025. This review synthesizes findings from studies assessing agents such as semaglutide, liraglutide, tirzepatide, and exenatide in diverse populations, including adults with and without type 2 diabetes and adolescents with severe obesity. Most studies demonstrated sustained weight loss and favorable glycemic control over treatment durations of 40-120 weeks. Additionally, the agents showed generally acceptable safety profiles, with gastrointestinal side effects being the most fre

    Save this paper

  15. Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.

    Meeti Mehta, David Rometo, Jeffrey A. Gusenoff, et al. · 2025 · Plastic and reconstructive surgery · 6 citations

    SUMMARY With obesity affecting over 40% of U.S. adults, bariatric surgery (BS) has become a cornerstone treatment, leading to massive weight loss (MWL) but also significant nutritional challenges. As demand for body contouring surgery (BCS) grows among post-BS patients, plastic surgeons must understand how evolving weight loss strategies, particularly the widespread use of GLP-1 receptor agonists and the shift to laparoscopic sleeve gastrectomy (LSG), impact nutritional status and wound healing. Unlike Roux-en-Y gastric bypass (RYGB), LSG presents fewer malabsorptive risks but still predisposes patients to deficiencies in iron, B12, and protein due to reduced intake and food intolerance.The

    Save this paper

  16. A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass

    F. Moscucci, Francesco Baratta, Daniele Pastori, et al. · 2026 · Nutrients · 5 citations

    Obesity in women over 65 represents a growing clinical challenge, particularly due to its association with increased risks of cardiovascular disease, osteoarthritis, frailty, sleep-breathing disorders, and sarcopenia. The prevalence of obesity in this demographic is compounded by age-related metabolic changes and declining physical activity. In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, have emerged as promising pharmacological treatments for weight loss, showing substantial efficacy in reducing body weight and improving metabolic health. However, their use in older populations warrants careful consideration due to the potential

    Save this paper

  17. Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report

    Ali Zahir, David Collins, Seyvonne Ip, et al. · 2025 · BMC Neurology · 5 citations

    GLP-1 agonists have been a welcome addition to the armamentarium in the treatment of diabetes and obesity. While this class of medications is generally considered safe and effective, potentially severe neurological complications may be associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use. We present a 37-year-old woman who was prescribed semaglutide for diabetes and weight loss who subsequently experienced significant weight reduction and rapid glycemic control over three months. Thereafter, she developed progressive right leg numbness and weakness, followed by similar symptoms in the left leg, and blurred vision. Initially diagnosed with B12 deficiency,

    Save this paper

  18. 847-P: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

    JINZI JASON WU, CHENGFEI WU · 2025 · Diabetes · 2 citations

    Introduction and Objective: ASC47 (selective THR-β agonist) is an adipose-targeted, once-monthly subcutaneously (SQ) injected, muscle-preserving weight loss drug candidate for the treatment of obesity, discovered and developed in-house at Ascletis. This study in diet-induced obese (DIO) mice demonstrated a powerful synergy in weight loss and muscle preservation when combining ASC47 and semaglutide. Methods: C57BL/6J mice were fed a high-fat diet for 16 weeks and received different treatments for 28 days. Body weight and food intake were recorded daily. Body composition was assessed by EchoMRI weekly. Results: ASC47 low dose combination 1 demonstrated superior we

    Save this paper

  19. 806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications

    Hala Zakaria, M. Caccelli, C. Ozkan, et al. · 2024 · Diabetes · 1 citations

    Anti-obesity GLP-1 agonists have widely been used by providers without emphasis on behavioral modification due to the short term effectiveness of these medications. The misuse of these medications without any monitored guidance on lifestyle changes can lead to significant weight regain. In this study, we will evaluate newer hybrid care models involving continuous engagement by multidisciplinary care teams on weight loss among those with pre-diabetes.This is a retrospective observational study of medical records for Zone.Health, a 6 months hybrid medicated obesity program, prescribed with both GLP-1 medications and multidimensional lifestyle modification (n=112). Behavioral change aspects of

    Save this paper

  20. Abstract 4366419: GLP-1 Receptor Agonist Semaglutide Improves Hepatic Metabolism and Reverses Hepatic Steatosis Independent of Weight Loss in Cardiometabolic HFpEF

    Natalie D. Gehred, Tatiana Gromova, Mahmoud H. Elbatreek, et al. · 2025 · Circulation

    Background: The GLP-1 receptor agonist, semaglutide, was shown to be beneficial in obese (STEP HFpEF) and diabetic (STEP HFpEF DM) patients suffering from heart failure with preserved ejection fraction (HFpEF), presumably secondary to anti-obesity effects. Challenging this assumption, we observed that a low dose of semaglutide, which does not impact body weight in a rat model, ameliorates cardiac HFpEF symptoms including diastolic dysfunction, fibrosis and exercise capacity. We sought to determine whether semaglutide could rescue hepatic symptoms of HFpEF, and if so, determine the molecular underpinnings. Hypothesis: GLP-1 receptor agonism improves the hepatic phenotypes in HFpEF vi

    Save this paper

  21. 1050-P: Revolutionary GLP-1 Weight Loss Medicine Semaglutide—To Cover or Not to Cover?

    Wenhao Lu, A. Xie, Yimei You · 2025 · Diabetes

    Introduction and Objective: We created a data-driven prioritizing system to determine which groups of patients benefit most by insurance coverage of Semaglutide based on short- and long-term cost effectiveness in managing obesity and related chronic diseases. This prioritizing model will enhance societal health outcomes and promote equitable access compared to current affordability-based coverage models. Methods: This study uses a retrospective cohort design with CDC survey data from 2019-2023. We analyzed the prevalence of obesity-related diseases across different weight groups to simulate the potential effectiveness of Semaglutide in managing chronic conditions. Correlation analysis was u

    Save this paper

  23. COMPARISON OF PHARMACOLOGICAL INTERVENTIONS WITH GLP-1, GIP, IGLUCAGON, BEHAVIORAL AND SURGICAL APPROACHES TO OBESITY IN WEIGHT LOSS AND WEIGHT REGAIN

    Darley Wilson Dias, Susan Ramos Lima, Letícia Rodrigues da Paixão Lopes, et al. · 2026 · Artefactum - revista de estudos interdisciplinares

    Introduction: Obesity is a chronic, multifactorial, and relapsing disease that represents a major public health challenge and cardiometabolic risk. Objective: To evaluate the effect of different therapeutic strategies in the treatment of obesity, comparing pharmacological interventions based on GLP-1 receptor agonists, dual GLP-1/GIP agonists, and therapies involving the glucagon axis, as well as behavioral and surgical approaches, regarding weight loss and weight regain. Method: Integrative review using studies addressing pharmacological, behavioral, and surgical interventions in obesity management, as well as their effects on weight loss and recovery. Results: Bariatric surgery demonstrate

    Save this paper

  24. New generations of GLP-1 agonists in the treatment of obesity: Evolution of weight-loss pens and clinical impact

    Jamile Zampieri Fernandes, Evelise Cargnin Trebien, Lívia Alves da Silva, et al. · 2026 · International Health Sciences Review

    Obesity is a chronic, relapsing, multifactorial disease associated with substantial cardiometabolic, hepatic, renal, and functional burden, yet for decades pharmacologic treatment remained limited by modest efficacy, poor tolerability, or cardiovascular safety concerns. This narrative review examined the evolution of incretin-based therapies for obesity, with emphasis on glucagon-like peptide-1 (GLP-1) receptor agonists and newer multiagonists. A literature review was conducted using PubMed, SciELO, and Cochrane, prioritizing landmark randomized clinical trials, extension studies, meta-analyses, guidelines, and regulatory documents related to liraglutide, semaglutide, tirzepatide, retatrutid

    Save this paper

Write your paper with these sources

Folio is the integrity-first research workspace: search 200M+ papers, save sources, and write with citations that format themselves. Free for students and researchers.

Start writing free →